Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meera Mohan

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
European Journal of Haematology|August 11, 2021
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)Dante Pennipede, Ghulam Rehman Mohyuddin, Ryan Hawkins, et al.
European Journal of Haematology|July 10, 2022
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccinationAl-Ola Abdallah, Zahra Mahmoudjafari, Tahani Atieh, et al.
Transplantation and Cellular Therapy|September 20, 2024
Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell TransplantationOthman S Akhtar, Shanze Arshad, Qinghua Lian, et al.
Blood Cancer Journal|January 25, 2024
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic reviewKarun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, et al.
British Journal of Haematology|October 13, 2024
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myelomaStephanie Yohay, Temitope Oloyede, Soyoung Kim, et al.
Blood Neoplasia|June 24, 2025
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myelomaAmrita Y Krishnan, Krina K Patel, Meera Mohan, et al.
Blood Advances|July 21, 2025
IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levelsRahul Banerjee, Meera Mohan, Kai Rejeski, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 29, 2019
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomesMeera Mohan, Sandra Susanibar-Adaniya, Amy Buros, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2022
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple MyelomaTahani Atieh, Shebli Atrash, Nausheen Ahmed, et al.
Bone|February 8, 2021
Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experienceMeera Mohan, Manoj Kumar, Rohan Samant, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|August 11, 2021
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)Dante Pennipede, Ghulam Rehman Mohyuddin, Ryan Hawkins, et al.
European Journal of Haematology|July 10, 2022
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccinationAl-Ola Abdallah, Zahra Mahmoudjafari, Tahani Atieh, et al.
Transplantation and Cellular Therapy|September 20, 2024
Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell TransplantationOthman S Akhtar, Shanze Arshad, Qinghua Lian, et al.
Blood Cancer Journal|January 25, 2024
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic reviewKarun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, et al.
British Journal of Haematology|October 13, 2024
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myelomaStephanie Yohay, Temitope Oloyede, Soyoung Kim, et al.
Blood Neoplasia|June 24, 2025
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myelomaAmrita Y Krishnan, Krina K Patel, Meera Mohan, et al.
Blood Advances|July 21, 2025
IVIG prophylaxis should be initiated following bispecific antibody therapy in multiple myeloma regardless of IgG levelsRahul Banerjee, Meera Mohan, Kai Rejeski, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 29, 2019
Bacteremias following autologous stem cell transplantation for multiple myeloma: Risk factors and outcomesMeera Mohan, Sandra Susanibar-Adaniya, Amy Buros, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2022
Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple MyelomaTahani Atieh, Shebli Atrash, Nausheen Ahmed, et al.
Bone|February 8, 2021
Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experienceMeera Mohan, Manoj Kumar, Rohan Samant, et al.
Pageof 7